[1] Garg P, Swift A J, Zhong L, et al. Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging[J]. Nature Reviews Cardiology, 2020, 17(5):298-312. [2] Na H B, Song I C, Hyeon T. Inorganic Nanoparticles for MRI Contrast Agents[J]. Advanced Materials, 2009, 21(21):2133-2148. [3] Li H, Meade T J. Molecular magnetic resonance imaging with Gd(Ⅲ)-based contrast agents:challenges and Key advances[J]. Journal of the American Chemical Society, 2019, 141(43):17025-17041. [4] Runge V M. Critical questions regarding gadolinium deposition in the brain and body after injections of the gadolinium-based contrast agents, safety, and clinical recommendations in consideration of the EMA's pharmacovigilance and risk assessment committee recommendation for suspension of the marketing authorizations for 4 linear agents[J]. Investigative Radiology, 2017, 52(6):317-323. [5] Wang J, Jia Y H, Wang Q Y, et al. An ultrahigh-field-tailored T1-T2 dual-mode MRI contrast agent for high-performance vascular imaging[J]. Advanced Materials, 2021, 33(2):2004917. [6] Chen H M, Qiu Y W, Ding D D, et al. Gadolinium-encapsulated graphene carbon nanotheranostics for imaging-guided photodynamic therapy[J]. Advanced Materials, 2018, 30(36):1802748. [7] Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?[J]. Nephrology Dialysis Transplantation, 2006, 21(4):1104-1108. [8] Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis:suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging[J]. Journal of the American Society of Nephrology, 2006, 17(9):2359-2362. [9] Mi P, Kokuryo D, Cabral H, et al. A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy[J]. Nature Nanotechnology, 2016, 11(8):724-730. [10] Zhu L P, Yang Y, Farquhar K, et al. Surface modification of Gd nanoparticles with pH-responsive block copolymers for use as smart MRI contrast agents[J]. ACS Applied Materials & Interfaces, 2016, 8(7):5040-5050. [11] Tang X X, Gong X Q, Ming J, et al. Fluorinated gadolinium chelate-grafted nanoconjugates for contrast-enhanced T1-weighted 1H and pH-activatable 19F dual-modal MRI[J]. Analytical Chemistry, 2020, 92(24):16293-16300. [12] Zhou T T, Wan G F, Li B, et al. Nanocomposites of ionic copolymer integrating Gd-containing polyoxometalate as a multiple platform for enhanced MRI and pH-response chemotherapy[J]. Journal of Materials Chemistry B, 2020, 8(30):6390-6401. [13] Nahrendorf M, Sosnovik D, Chen J W, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury[J]. Circulation, 2008, 117(9):1153-1160. [14] Nejadnik H, Ye D J, Lenkov O D, et al. Magnetic resonance imaging of stem cell apoptosis in arthritic joints with a caspase activatable contrast agent[J]. ACS Nano, 2015, 9(2):1150-1160. [15] Wahsner J, Gale E M, Rodríguez-Rodríguez A, et al. Chemistry of MRI contrast agents:current challenges and new frontiers[J]. Chemical Reviews, 2019, 119(2):957-1057. [16] Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction:evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy[J]. Radiology, 2015, 276(1):228-232. [17] Kim K S, Park W, Hu J, et al. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle[J]. Biomaterials, 2014, 35(1):337-343. [18] Pellico J, Ellis C M, Miller J, et al. Water gated contrast switching with polymer-silica hybrid nanoparticles[J]. Chemical Communications, 2019, 55(59):8540-8543. [19] Hu X, Liu G, Li Y, et al. Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals[J]. Journal of the American Chemical Society, 2015, 137(1):362-368. [20] Viger M L, Sankaranarayanan J, De Gracia Lux C, et al. Collective activation of MRI agents via encapsulation and disease-triggered release[J]. Journal of the American Chemical Society, 2013, 135(21):7847-7850. [21] Esqueda A C, López J A, Andreu-De-Riquer G, et al. A new gadolinium-based MRI zinc sensor[J]. Journal of the American Chemical Society, 2009, 131(32):11387-11391. [22] Lubag A J M, de Leon-Rodriguez L M, Burgess S C, et al. Noninvasive MRI of β-cell function using a Zn2+-responsive contrast agent[J]. PNAS, 2011, 108(45):18400-18405. [23] Martins A F, Clavijo Jordan V, Bochner F, et al. Imaging insulin secretion from mouse pancreas by MRI is improved by use of a zinc-responsive MRI sensor with lower affinity for Zn2+ ions[J]. Journal of the American Chemical Society, 2018, 140(50):17456-17464. [24] Su H S, Nahrendorf M, Panizzi P, et al. Vasculitis:Molecular imaging by targeting the inflammatory enzyme myeloperoxidase[J]. Radiology, 2012, 262(1):181-190. [25] Ye D, Shuhendler A J, Pandit P, et al. Caspase-responsive smart gadolinium-based contrast agent for magnetic resonance imaging of drug-induced apoptosis[J]. Chemical Science, 2014, 4(10):3845-3852. [26] Shuhendler A J, Ye D, Brewer K D, et al. Molecular magnetic resonance imaging of tumor response to therapy[J]. Scientific Reports, 2015, 5:14759. [27] Hermann P, Kotek J, Kubí[XCZ1.TIF]ek V, et al. Gadolinium (Ⅲ) complexes as MRI contrast agents:ligand design and properties of the complexes[J]. Dalton Transactions, 2008, (23):3027-3047. [28] Manus L M, Strauch R C, Hung A H, et al. Analytical methods for characterizing magnetic resonance probes[J]. Analytical Chemistry, 2012, 84(15):6278-6287. [29] Major J L, Parigi G, Luchinat C, et al. The synthesis and in vitro testing of a zinc-activated MRI contrast agent[J]. PNAS, 2007, 104(35):13881-13886. [30] Major J L, Boiteau R M, Meade T J. Mechanisms of ZnII-activated magnetic resonance imaging agents[J]. Inorganic Chemistry, 2008, 47(22):10788-10795. [31] Dhingra K, Maier M E, Beyerlein M, et al. Synthesis and characterization of a smart contrast agent sensitive to calcium[J]. Chemical Communications, 2008, (29):3444-3446. [32] Li W S, Luo J, Chen Z N. A gadolinium(Ⅲ) complex with 8-amidequinoline based ligand as copper(Ⅱ) ion responsive contrast agent[J]. Dalton Transactions, 2011, 40(2):484-488. [33] Duimstra J A, Femia F J, Meade T J. A gadolinium chelate for detection of beta-glucuronidase:a self-immolative approach[J]. Journal of the American Chemical Society, 2005, 127(37):12847-12855. [34] Giardiello M, Lowe M P, Botta M. An esterase-activated magnetic resonance contrast agent[J]. Chemical Communications, 2007, (39):4044-4046. [35] Garello F, Vibhute S, Gündüz S, et al. Innovative design of ca-sensitive paramagnetic liposomes results in an unprecedented increase in longitudinal relaxivity[J]. Biomacromolecules, 2016, 17(4):1303-1311. [36] Warburg O, Wind F, Negelein E. The metabolism of tumors in the body[J]. The Journal of general physiology, 1927, 8(6):519-530. [37] Wojtkowiak J W, Verduzco D, Schramm K J, et al. Drug resistance and cellular adaptation to tumor acidic pH microenvironment[J]. Molecular Pharmaceutics, 2011, 8(6):2032-2038. [38] Gupta S C, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species for cancer:the roles of reactive oxygen species in tumorigenesis, prevention, and therapy[J]. Antioxidants & Redox Signaling, 2012, 16(11):1295-1322. [39] Gong F, Yang N L, Wang X W, et al. Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics[J]. Nano Today, 2020, 32:100851. [40] Meng F H, Hennink W E, Zhong Z Y. Reduction-sensitive polymers and bioconjugates for biomedical applications[J]. Biomaterials, 2009, 30(12):2180-2198. [41] Fu Y, Jang M S, Wang N N, et al. Dual activatable self-assembled nanotheranostics for bioimaging and photodynamic therapy[J]. Journal of Controlled Release, 2020, 327:129-139. [42] Song Q L, Jia J J, Niu X X, et al. An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy[J]. Nanoscale, 2019, 11(34):15958-15970. [43] Raghunand N, Howison C, Sherry A D, et al. Renal and systemic pH imaging by contrast-enhanced MRI[J].Magnetic Resonance in Medicine, 2003, 49(2):249-257. [44] de Leon-Rodriguez L M, Lubag A J M, Malloy C R, et al. Responsive MRI agents for sensing metabolism in vivo[J]. Accounts of Chemical Research, 2009, 42(7):948-957. |